A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2118 participants.

Also called NCT01018173

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,118 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01018173
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Brazil, Bulgaria, Canada, Czechia, Denmark, Estonia, Germany, Hungary, India, Israel, Lithuania, Malaysia, Mexico, Poland, Romania, Russia, Slovakia, South Africa, Spain, Taiwan, Thailand, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01018173. Randomized; double masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2011-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease
Condition
Diabetes Mellitus Type 2
Intervention (Drug)
placebo
Intervention (Drug)
taspoglutide
Lead sponsor
Hoffmann-La Roche (class: industry)

Record details

Record id
cardio:ct-nct01018173
Content hash
2cc7965c34c3ec445f6f53a2be3ea52d4181349ce1336503b671f0f91b14dbf4